Association of Fibrate Use with Clinical Expression of Hypertrophic Cardiomyopathy
ESC Heart Failure · 2024
DOI: 10.1002/ehf2.15004 ↗Kurz gefasst
Fachartikel in der Zeitschrift ESC Heart Failure, 2024. Verfasst von Chan Soon Park und 9 weiteren Autor:innen. Beteiligte Einrichtung: Cardiovascular Center, Seoul National University Hospital, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Cardiomyopathy, Hypertrophic, Fibric Acids. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Seoul National University 2021 Research Fund.
Abstract (Originalsprache)
Aims
An association between obesity, metabolic abnormalities and clinical hypertrophic cardiomyopathy (HCM) expression has been reported. We investigated whether managing dyslipidaemia with fibrates could affect the clinical expression of HCM.
Methods
We screened patients who used fibrates between 2010 and 2017 from a nationwide database. After excluding patients with a history of HCM, we identified fibrate-user group (n = 412 823). We then constructed a 1:1 matched cohort of fibrate-naïve participants (n = 412 823). After a 1 year lag period, we identified the incident HCM cases for the following 5 years.
Results
During a median follow-up period of 3.96 years, we identified 454 incident clinical HCM cases. After adjusting for covariates, fibrate use was associated with a lower risk of clinical HCM expression [hazard ratio (HR) 95% confidence interval (CI): 0.763 (0.630–0.924)]. In subgroup analyses, fibrate use was associated with a reduced risk of clinical HCM expression in patients with a body mass index ≥25 kg/m2 and those with abdominal obesity [HR (95% CI): 0.719 (0.553–0.934) and 0.655 (0.492–0.872)], but not in those without obesity. Fibrate use was also associated with lower risks of incident clinical HCM in patients with triglyceride levels ≥150 mg/dL and those with metabolic syndrome [HR (95% CI): 0.741 (0.591–0.929) and 0.750 (0.609–0.923)], but not in their counterparts. Regarding lifestyle behaviours, fibrate use appeared to provide more prognostic benefits in patients who currently smoked, consumed alcohol or did not engage in regular physical activities.
Conclusion
The use of fibrates is associated with a lower incidence of clinical HCM expression. This association was also more prominent in those with obesity, unhealthy metabolic profiles and poor lifestyle behaviours.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cardiovascular Center, Seoul National University Hospital, Seoul, Republic of Korea.
- Department of Statistics and Actuarial Science, Soongsil University, Seoul, Republic of Korea.
- Cardiovascular Center, Seoul National University Hospital Healthcare System Gangnam Center, Seoul, Republic of Korea.
ORCID-Profile: Hyung-Kwan Kim
Förderung
- Seoul National University 2021 Research Fund
Zitieren
APA
Park, C. S., Kim, B., Jung, J. H., Rhee, T. M., Lee, H. J., Lee, H. S., Park, J. B., Kim, Y. J., Han, K., & Kim, H. K. (2024). Association of Fibrate Use with Clinical Expression of Hypertrophic Cardiomyopathy. ESC Heart Failure. https://doi.org/10.1002/ehf2.15004
Vancouver
Park CS, Kim B, Jung JH, Rhee TM, Lee HJ, Lee HS, et al. Association of Fibrate Use with Clinical Expression of Hypertrophic Cardiomyopathy. ESC Heart Failure. 2024. doi:10.1002/ehf2.15004
BibTeX
@article{Park2024,
author = {Park, Chan Soon and Kim, Bongseong and Jung, Jin-Hyung and Rhee, Tae-Min and Lee, Hyun Jung and Lee, Hee-Sun and Park, Jun-Bean and Kim, Yong-Jin and Han, Kyungdo and Kim, Hyung-Kwan},
title = {Association of Fibrate Use with Clinical Expression of Hypertrophic Cardiomyopathy},
journal = {ESC Heart Failure},
year = {2024},
doi = {10.1002/ehf2.15004}
}
EUVIMED